CrossRef GLP1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study Jisu Park, Ju Hwan Kim, Yoon Seob Kim, Gyeongmin Lim, Hong Ji Song, Sang Youl Rhee, Seonghoon Hwang, Daeun Cho, Minyoung Kim, BoYeon Kim, Chang Won Jeong, DaeYeon Kim, Hang A Park, MinHo Kim, Seong Hwan Kim, WonWoo Seo, Woo Jin Kim, Young Sung Suh, Ra Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef GlucagonLike Peptide1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yongho Lee, Seng Chan You Diabetes, Obesity and Metabolism.2026;[Epub] CrossRef Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care Paola Mogna-Pelez, Marta Guasch-Ferr The Journal of Nutrition.2026
Monitoring for Common Side Effects During Dose Increases As doses go up, side effects like nausea, vomiting, stomach upset, or fatigue may appear
Characterization of duodenal expression and localization of fatty acid-sensing receptors in humans: relationships with body mass index
Hernndez-Daz said
Method of Administration: Semaglutide is given as a subcutaneous injection, which means it is injected under the skin
Below, well cover the fundamentals of GLP-1 safety, from evidence-based best practices to a look at some of the newer, buzzworthy trends like supplements and microdosing
